Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
11,577,066
-
Total 13F shares
-
399,983
-
Share change
-
+121,452
-
Total reported value
-
$711,810
-
Price per share
-
$1.78
-
Number of holders
-
8
-
Value change
-
+$221,594
-
Number of buys
-
7
-
Number of sells
-
4
Institutional Holders of Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) as of Q3 2025
As of 30 Sep 2025 Apimeds Pharmaceuticals US, Inc. - Common Stock (APUS) had 8 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 399,983 shares of stock of the company.
Largest 8 holders included Hemenway Trust Co LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, XTX Topco Ltd, HRT FINANCIAL LP, BANK OF AMERICA CORP /DE/, and JPMORGAN CHASE & CO.
This table shows 8 institutional shareholders of the security as of 30 Sep 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.